SNP-SNP interaction analysis of NF-kappa B signaling pathway on breast cancer survival
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | SNP-SNP interaction analysis of NF-kappa B signaling pathway on breast cancer survival |
Type de publication | Journal Article |
Year of Publication | 2015 |
Auteurs | Jamshidi M, Fagerholm R, Khan S, Aittomaki K, Czene K, Darabi H, Li J, Andrulis IL, Chang-Claude J, Devilee P, Fasching PA, Michailidou K, Bolla MK, Dennis J, Wang Q, Guo Q, Rhenius V, Cornelissen S, Rudolph A, Knight JA, Loehberg CR, Burwinkel B, Marme F, Hopper JL, Southey MC, Bojesen SE, Flyger H, Brenner H, Holleczek B, Margolin S, Mannermaa A, Kosma V-M, Van Dyck L, Nevelsteen I, Couch FJ, Olson JE, Giles GG, Mclean C, Haiman CA, Henderson BE, Winqvist R, Pylkas K, Tollenaar RAEM, Garcia-Closas M, Figueroa J, Hooning MJ, Martens JWM, Cox A, Cross SS, Simard J, Dunning AM, Easton DF, Pharoah PDP, Hall P, Blomqvist C, Schmidt MK, Nevanlinna H, Investigators KCF |
Journal | ONCOTARGET |
Volume | 6 |
Pagination | 37979-37994 |
Date Published | NOV 10 |
Type of Article | Article |
Mots-clés | Breast cancer, NF-kappa B pathway, SNP-SNP interaction, Survival analysis |
Résumé | {In breast cancer, constitutive activation of NF-kappa B has been reported, however, the impact of genetic variation of the pathway on patient prognosis has been little studied. Furthermore, a combination of genetic variants, rather than single polymorphisms, may affect disease prognosis. Here, in an extensive dataset (n = 30,431) from the Breast Cancer Association Consortium, we investigated the association of 917 SNPs in 75 genes in the NF-kappa B pathway with breast cancer prognosis. We explored SNP-SNP interactions on survival using the likelihood-ratio test comparing multivariate Cox' regression models of SNP pairs without and with an interaction term. We found two interacting pairs associating with prognosis: patients simultaneously homozygous for the rare alleles of rs5996080 and rs7973914 had worse survival (HRinteraction 6.98, 95% CI= 3.3-14.4 |
DOI | 10.18632/oncotarget.4991 |